Kazuyo Yoshida

Real-world event-free survival with neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab in early-stage triple-negative and estrogen receptor-low, HER2-negative breast cancer

Neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab has become a standard treatment for patients with early-stage triple-negative breast cancer (TNBC) based on the KEYNOTE-522 trial; however, real-world data on event-free survival (EFS) remain limited. We aimed...